Inhaled nitric oxide (iNO) is an effective adjunct in the treatment of infants with respiratory failure. Although there are clear benefits to this therapy, potential toxicity could result from reactive nitrosylated species.
INTRODUCTION
Term infants experience substantial morbidity and mortality from respiratory failure. 1, 2 This condition can result from meconium aspiration or infection complicated by persistent pulmonary hypertension of the newborn among other causes. 3 Recent clinical trials have demonstrated that the endogenous vasodilator nitric oxide (NO) may be a useful adjunct in the treatment of term infants with respiratory failure and decreases the need for extracorporeal membrane oxygenation. [4] [5] [6] Despite the known benefits of iNO, there are also theoretical considerations as to the effects of NO on oxidative stress since NO can combine with molecular oxygen to form nitrogen dioxide at a rate dependent on the concentration of oxygen and the square of the concentration of NO. 7, 8 Additionally, NO can react with superoxide radicals to form a secondary stable cytotoxic species, peroxynitrite, which eventually decomposes to NO and the hydroxyl radical, a highly toxic and reactive molecule. 9 In animals, the combination of oxygen with NO resulted in increased toxicity in a ventilated piglet model. 9 In contrast, NO significantly reduced oxygen toxicity at low doses (5 to 10 parts per million (p.p.m.)) in a rat model 10 and did not worsen oxidative stress in a premature lamb model. 11 In human studies, increased nitrotyrosine residues were observed in the serum of premature infants receiving iNO who developed chronic lung disease (CLD). 12 It has been suggested that NO in the presence of superoxide can inactivate surfactant protein A. 13 This may account in part for the NO-mediated lung injury. The purpose of this study was to evaluate the effects of iNO on markers of oxidative stress. Serum samples were obtained from full term infants with severe respiratory distress treated with iNO. These were compared to values in air exposed controls as well as infants treated with oxygen alone. The serum samples were assayed for markers of oxidative injury. The incidence of CLD, defined as the need for oxygen at 30 days, was also recorded.
MATERIALS AND METHODS Patient Selection
Serum samples were obtained from three groups of infants after parental consent. All of the infants were greater than 36 weeks gestation, less than 7 days of age and had serum bilirubin levels of less than 10 mg/dl. The ''room air'' cohort consisted of infants in room air with no prior oxygen treatment. The ''oxygen-exposed'' cohort were infants with respiratory failure in > 80% oxygen for more than 6 hours. The ''iNO'' cohort were infants who had received iNO and had serum samples drawn after approximately 1, 24 and 48 hours of iNO therapy.
iNO Therapy All infants receiving iNO were participating in the open label phase of the Neonatal Inhaled Nitric Oxide Study. 5 In this trial, therapy with 20 p.p.m. iNO was initiated when eligibility criteria were met. These included reaching an oxygenation index of greater than 25 on two measurements obtained at least 15 minutes apart. A full response was defined as an increase in blood oxygen of more than 20 millimeters of mercury (mm Hg); a partial response was defined as an increase in blood oxygen of 10 to 20 mmHg and no response was defined as an increase of less than 10 mmHg of blood oxygen 30 minutes after iNO exposure. When the infant had less than a complete response, iNO was then administered at 80 p.p.m. and an arterial blood gas was again measured after 30 minutes. Infants with full responses continued to receive 80 p.p.m. iNO; infants with partial responses received the lowest concentration of iNO that produced at least a partial response. If there was no response to either 20 or 80 p.p.m., iNO was discontinued. After 12 hours of iNO therapy, the iNO dose was decreased by 50% every 12 hours until a dose of 5 p.p.m. was reached and then was weaned by 1 p.p.m. every 12 hours.
Primary grade NO was supplied at 800 p.p.m. with nitrogen (Ohmeda, Liberty Corner, NJ). The gas was certified to contain less than 5 p.p.m. of nitrogen dioxide. NO was titrated into the ventilator circuit and the gas mixture was continuously sampled at 50 cm distal to the injection site on the inspiratory limb of the ventilator circuit just prior to the endotracheal tube using either a chemiluminescence analyzer (ECOPhysics model CLD 700 AL, Durten, Switzerland) or an electrochemical sensor (Pulmonox II, Pulmonox, Tolfield, Alta, Canada) to measure both NO and nitrogen dioxide.
For each patient, the cumulative number of p.p.m. hours of iNO therapy as well as the hours in greater than 80% oxygen were calculated at the time each serum sample was drawn.
Assays
All serum samples were assayed for lipid hydroperoxides (LPO), glutathione (GSH), nitrotyrosine residues, protein carbonyls and total antioxidant status (TAS) as described below.
Measurement of LPO. Serum LPO was measured using the Determiner LPO-CC kit (Kamiya Biomedical Company, Thousand Oaks, CA) for the determination of lipid hydroperoxides in the serum. This assay is based on the reaction of LPO with the methylene blue derivative (10-N-methylcarbamoyl-3, 7-dimethylamiNO-10 H-phenothiazine). The LPO determiner kit allows for the detection of lipid hydroperoxides. In the presence of hemoglobin, LPO are reduced to lipid alcohols that react with a chromogen after oxidative cleavage to form methylene blue. 14 Detection of GSH. Total serum GSH was measured using the Glutathione Assay kit Cat #703002 (Cayman Chemical Company, Ann Arbor, MI). GSH reacts with 5, 5 0 -dithiobis-2-nitrobenzoic acid, Ellman's reagent to produce a yellow colored product, 5-thio-2-nitrobenzoic acid. Measurement of the absorbance of thio-2-nitrobenzoic acid at 405 nm accurately measures GSH.
Nitrotyrosine residues. Nitration of tyrosine residues in proteins occurring in the presence of NO was detected by Western blotting. Serum samples were electrophoresed on a 12% polyacrylamide gel and transferred to polyvinyl difluoridine membrane blots. The samples were incubated overnight with rabbit polyclonal IgG anti-nitrotyrosine antibodies (Upstate Biotechnology, Lake Placid, NY) at a 1:1000 dilution in a 1% solution of bovine serum albumin in phosphate-buffered saline with 0.05% Tween-20. Blots were washed in 0.05% Tween-20 and incubated for 1 h at 251C with a 1:5000 dilution of horse radish peroxidase-conjugated goat anti-rabbit IgG. Antigen antibody complexes were visualized with the horse radish peroxidase chemiluminescence system according to the manufacturer's instructions (Bio-Rad). Quantification was performed by densitometry (Molecular Analyst image analysis software, Bio-Rad, Hercules, CA) and values were normalized to air exposed controls on each blot.
Protein carbonyls. Protein oxidation was measured by detecting oxidatively generated carbonyl groups using the OxyBlot Kit (Oncor, Gaithersburg, MD). Briefly, 20 mg protein aliquots, mixed with 1 volume of 12% sodium dodecyl sulfate, were incubated with two volumes of 1 Â 2,4-dinitrophenylhydrazine for 15 minutes at room temperature. The samples were then neutralized by addition of 1.5 volumes of neutralization solution (Oncor) and electrophoresed on a 12% polyacrylamide gel. After transfer to polyvinyl difluoridine membranes, blots were briefly washed in blocking buffer (1% bovine serum albumin in phosphate-buffered saline-0.05% Tween) for 1 hour and then incubated for 1 hour at 251C with rabbit anti-dinitrophenylhydrazine IgG diluted 1:150 in blocking buffer. Blots were washed in blocking buffer and incubated for 1 h at 251C with a 1:300 dilution of HRP-conjugated goat anti-rabbit IgG. The antigen-antibody signal was visualized by chemiluminescence using the horseradish peroxidase chemiluminescence system according to the manufacturer's instructions (Bio-Rad, Hercules, CA). The bands showing the most consistent signal in controls and samples were used for comparison between samples. Quantification was performed by densitometry.
Evaluation of TAS. Serum TAS was measured using the Total Antioxidant Status Kit (Randox Laboratories, Antrim, UK). In this assay, 2,2-AziNO-di-[3-ethylbenzthizoline sulfonate is incubated with peroxidase (metmyoglobin) and H 2 0 2 yielding a blue colored compound, which is quantitated colorimetrically at 600 nm. Serum antioxidants cause suppression of this reaction in proportion to their concentration.
RESULTS
A total of 108 samples were drawn from 81 patients entered in the study. All patients were of similar birth weight, gender and chronological age at the time of study entry. The iNO-exposed infants were at a more advanced gestational age (1 week) when compared to the room air control infants (Table 1 ). All patients were at least 36 weeks gestational age and no more than 7 days old. Since bilirubin pigment can interfere with the spectrophotometer measurements, it was important to determine bilirubin values. All values were less than 10 mg/dl upon study entry. In the room air control group, patient diagnoses included suspected sepsis, encephalocele, esophageal atresia, myelomeningocele, infant of a diabetic mother, transient tachypnea of the newborn, dehydration and polycythemia with the majority of infants (67%) admitted for suspected sepsis. Diagnoses in the oxygen-treated group included meconium aspiration syndrome, sepsis/pneumonia, perinatal depression, persistent pulmonary hypertension of the newborn, congenital diaphragmatic hernia, respiratory distress syndrome and blood aspiration. In the iNO group, diagnoses included meconium aspiration syndrome, sepsis/pneumonia, persistent pulmonary hypertension of the newborn, congenital diaphragmatic hernia and respiratory distress syndrome. The majority of the oxygen and iNO-exposed patients were diagnosed with meconium aspiration syndrome or sepsis/ pneumonia (56 and 66%, respectively).
Patients were exposed to >80% oxygen for 38±50.4 hours (oxygen group), 42.6±45.5 hours (NO-24 group) and 61.3±55.8 hours (NO-48 group). The incidence of CLD was 15% for the oxygen group and 40% for the iNO group. The oxygen exposure values were not statistically different for the groups and did not correlate with the incidence of CLD. In addition, the incidence of CLD also did not correlate with the cumulative dose of iNO. Infants with CLD had a mean of 2.2±2.6 p.p.m.-hours/100 exposure to iNO vs 3.6±4.0 p.p.m.-hours/100 in infants without CLD (P ¼ 0.41).
Serum LPO
Interestingly, exposure to oxygen alone was not associated with increased LPO compared to room air (Figure 1 ). In contrast, serum LPO was significantly increased after 24 hours of iNO. The mean LPO values for the infants receiving greater than 24 hours of iNO was 4.5 times greater than that of the oxygen group (Figure 1) . After 48 hours of iNO, serum LPO values were no longer statistically different from those of air and oxygen-exposed controls, suggesting a resolution of oxidative stress. Nonetheless, the cumulative iNO dose was correlated to serum LPO (R 2 ¼ 0.355; p ¼ 0.046) (Figure 2 ). However, one patient was a significant outlier due to low LPO values despite high cumulative exposure to iNO at 24 and 48 hours and accounted for two data points. Exclusion of this single patient resulted in an increased R 2 value of 0.52, p<0.0001.
Serum GSH Serum GSH levels were no different in the air and hyperoxiaexposed group. In the iNO group, no change in serum GSH was noted after 1 h(NO-1) or 24 hours (NO-24). After 48 hours (NO-48), serum GSH levels were significantly higher than all other groups ( Figure 3 ). 
Visualization of Serum Protein Carbonyl and Nitrotyrosine Residues
Serum protein carbonyls increased in infants exposed to iNO for 24 hours compared to infants exposed to room air, oxygen and 1 hour of iNO (Figure 4 ). Increased serum nitrotyrosine residues were observed in all iNO-exposed infants as compared to air-exposed controls ( Figure 5 ). At 24 hours, only the iNO samples were significantly different than those obtained from infants exposed to oxygen. Values represent the mean±SE of samples from each group. Room air: controls not exposed to oxygen (n ¼ 7); oxygen: patients exposed to >80% oxygen (n ¼ 7); NO-1: patients treated with iNO for 1 hour (n ¼ 7); NO-24: patients treated with iNO for 24 hours or greater (n ¼ 7); NO-48: patients treated with iNO for 48 hours or greater (n ¼ 7). *p<0.05 vs room air, oxygen and NO-1.
Correlation of Serum Markers with Chronic Lung

DISCUSSION
NO improves oxygenation and decreases the need for ECMO use in term and near-term in neonates with respiratory failure. [4] [5] [6] Although acute benefits are observed, potential deleterious effects could result when iNO-treated infants are also exposed to high concentrations of inspired oxygen because NO can interact with superoxide radicals to form toxic radicals. 15 We measured markers of oxidative injury in the serum of patients treated with iNO and observed increased serum markers of oxidative stress with longer exposures to iNO. We chose to look at lipid peroxidation as a marker of injury because this is a well-known index of oxidative injury. 16 Oxidative stress affects the phospholipase pathway resulting in oxidation of polyunsaturated fatty acids including arachidonic acid. This is detected with the lipid hydroperoxide assay.
14 Serum LPO was significantly increased in patients receiving iNO for greater than 24 hours compared to all other groups, but further exposure to iNO did not further increase LPO. This would suggest that iNO has acute pro-oxidative effects, but that these are short lived.
Most of the iNO-treated infants were also receiving high oxygen concentrations, therefore the observed changes in LPO may have been simply attributed to prolonged exposure to high oxygen. However, the oxygen-treated infants had relatively low serum LPO. Furthermore, the duration of high oxygen exposure did not differ between the oxygen and iNO groups at the time of iNO sampling. Therefore, we could not prove a cumulative effect of iNO and oxygen on markers of oxidative stress.
Several groups have shown that iNO has anti-inflammatory properties, which could ameliorate lung injury. 11, 17 This could explain the lack of sustained oxidative stress in the serum of patients with prolonged iNO exposure (greater than 24 hours). We did not specifically assess markers of inflammation to verify this.
The lack of difference in LPO between the hyperoxia and air control groups may result from the relatively heterogeneous nature of the room air control group. This group included many patients with suspected sepsis and therefore possible inflammation. Oxidative stress can result from inflammation. 18, 19 This could result in increased LPO in the controls. Furthermore, infants of diabetic mothers included in the group could have had increased lipid peroxidation with prenatal hyperglycemia. 20, 21 Ideally, the control group should have consisted of only healthy babies. However, obtaining blood samples on such a population would raise ethical concerns.
To further corroborate the findings of increased LPO, serum GSH was evaluated. Glutathione is an important thiol, which protects against oxidative injury. 22 The initial response to oxidative stress involves increased total GSH content due to induction of glutathione synthetic enzymes followed by later depletion. 23 Serum GSH levels were high after 48 hours of iNO, suggesting increased glutathione synthesis with mild oxidative stress.
The TAS reflects serum antioxidant capacity. Increased TAS suggests induction of antioxidant defenses. 24 An inverse correlation between this marker and the development of CLD has been documented. 25 In the present study, no differences in serum TAS were observed between groups suggesting that no significant change in total antioxidant capacity occurred despite an increased GSH.
Serum protein carbonyls are another useful marker of oxidative stress in ventilated infants. The presence of these modified proteins in tracheal aspirates in the first days of life correlated with adverse outcome and the development of chronic lung disease, 26, 27 but serum protein carbonyls did not. 28 Infants exposed to hyperoxia did not demonstrate increased protein carbonyls but exposure to iNO for greater than 24 hours was associated with significant increases in serum protein carbonyls further suggesting increased oxidative stress. Serum nitrotyrosine residues were also increased in infants treated with NO for 24 hours or greater but the oxygen-exposed infants also showed an increased protein nitrosylation. The decreasing trend in the protein carbonyls and nitrotyrosine residues with longer iNO exposure suggests that the oxidative stress Values represent the mean±SE of samples from each group. M: protein markers; room air: controls not exposed to oxygen (n ¼ 7); Oxygen: patients exposed to >80% oxygen (n ¼ 7); NO-1: patients treated with iNO for 1 hour (n ¼ 7); NO-24: patients treated with iNO for 24 hours or greater (n ¼ 7); NO-48: patients treated with iNO for 48 hours or greater (n ¼ 7). *p<0.05 vs room air controls. wp<0.05 vs oxygen exposed.
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resulting from iNO exposure is perhaps short-lived and overcome by endogenous mechanisms not identified here. Elevated nitration products correlates with the development of CLD in ventilated preterm newborns not exposed to iNO. 29 In this study, we did observe an increased incidence of CLD in the iNOtreated infants as compared to infants treated with oxygen only. However, there was no difference in the duration of oxygen exposure between the two groups and there was no correlation between cumulative iNO exposure and CLD. This suggests that the severity of illness rather than the exposure to oxygen or iNO correlates with the development of CLD. In addition, there was no correlation of LPO, GSH or TAS seen in individual patients and the development of CLD.
Others have implicated iNO exposure and subsequent increased nitrosylation of serum proteins in the onset of CLD in a small group of premature infants. 12 The present study involved term infants who have a considerably lower incidence of CLD than preterms. Demonstrating an effect of iNO on CLD in term infants would require a large patient population beyond the scope of this study. It is likely that we did not have sufficient power to detect a difference in CLD rates between the iNO and oxygen groups given the small size of the study. To this effect, three large randomized trials of iNO therapy in term and near-term infants have not demonstrated an increased incidence of CLD in the iNO-treated groups. [4] [5] [6] Furthermore, a single large randomized trial demonstrated a lower incidence of CLD in the iNO-treated group corroborating the absence of significant NO-mediated oxidative stress. 6 In conclusion, in term infants, we observed increased markers of oxidative stress with iNO exposure suggesting that iNO results in increased oxidative injury. The lack of a sustained increase in these markers except LPO suggests that these effects may be transient and not likely to result in chronic oxidative injury.
